Charles River Laboratories International, Inc. (CRL) is a publicly traded Healthcare sector company. As of August 27, 2026, CRL trades at $296.35 with a market cap of $14.09B and a P/E ratio of -62.19. CRL moved +0.44% today. Year to date, CRL is +46.43%; over the trailing twelve months it is +82.07%. Its 52-week range spans $91.86 to $303.31. Analyst consensus is strong buy with an average price target of $284.64. Rallies surfaces CRL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest CRL news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $296.35 |
| Market Cap | $14.09B |
| P/E Ratio | -62.19 |
| EPS | $-4.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $303.31 |
| 52-Week Low | $91.86 |
| Volume | 784.53K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.00B |
| Net Income | $-236.30M |
| Gross Margin | 0.00% |
13 analysts cover CRL: 0 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $284.64.